Dupixent (dupilumab) is a biologic medication prescribed for eczema, asthma, and other inflammatory conditions. Recent studies and adverse event reports have linked Dupixent to an increased risk of cutaneous T-cell lymphoma (CTCL), a rare and serious form of skin cancer — yet the drug’s warning label still makes no mention of this risk.
Lawsuits are now being filed against Dupixent’s manufacturers, Sanofi and Regeneron Pharmaceuticals, alleging they failed to adequately warn patients and doctors about the connection between Dupixent and CTCL. The Higgins Firm is actively investigating these claims on behalf of patients in Tennessee and nationwide.
If you or a loved one took Dupixent and were later diagnosed with CTCL or T-cell lymphoma, contact The Higgins Firm for a free case review. There are no upfront costs — you only pay if we recover compensation for you.
Table of Contents
Dupixent works by blocking two immune system proteins — interleukin-4 (IL-4) and interleukin-13 (IL-13) — that drive type 2 inflammation. The FDA first approved it in 2017 for moderate-to-severe atopic dermatitis, and its approved uses have since expanded to include asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and COPD.
The problem is that CTCL, in its early stages, looks almost identical to eczema. The same red, scaly, itchy patches. The same persistent rashes. Even experienced dermatologists can struggle to tell the two conditions apart without a biopsy.
Lawsuits allege that Dupixent may suppress the visible symptoms of an undiagnosed CTCL — giving both patients and doctors the false impression that the drug is working, while cancer progresses undetected underneath.
Researchers have identified several ways Dupixent may contribute to CTCL development or progression:
Because CTCL mimics the very conditions Dupixent is prescribed to treat, patients had no reason to suspect anything was wrong — and Sanofi and Regeneron provided no warning that they should.
Cutaneous T-cell lymphoma is a type of non-Hodgkin lymphoma that begins in white blood cells called T-cells and primarily affects the skin. The two most common subtypes are mycosis fungoides, which progresses slowly and presents as scaly patches, plaques, or tumors on the skin, and Sézary syndrome, a more aggressive form that affects both the skin and blood.
Early symptoms of CTCL include persistent rashes, dry or red patches, skin thickening, itching that doesn’t respond to standard treatment, and discoloration. As the disease advances, it can spread to the lymph nodes, blood, and internal organs.
CTCL is rare — roughly 3,000 new cases are diagnosed annually in the U.S. — and typically affects adults over 50. However, studies indicate that Dupixent-related CTCL cases are appearing in younger patients and that the majority of diagnoses occur within the first year of starting the drug.
The connection between Dupixent and CTCL is supported by multiple peer-reviewed studies and a growing body of FDA adverse event data.
Journal of the American Academy of Dermatology (2024): A retrospective cohort study found that eczema patients treated with Dupixent were 4.1 times more likely to be diagnosed with CTCL than patients not treated with the drug. The increased risk persisted even after patients discontinued Dupixent.
Dermatologic Therapy (2024): An analysis of over 39,000 patients found a relative risk of 4.59 for CTCL among Dupixent users. Nearly half of the diagnosed patients were under 60, and 62% were diagnosed within the first year of use.
European Respiratory Journal (2025): A population-based study expanded the scope to asthma patients, finding that those treated with Dupixent had a 4.5-fold higher risk of CTCL compared to patients treated with inhaled corticosteroids and long-acting beta agonists. Among patients who continued treatment for at least 16 weeks, the risk of mature T-cell and NK-cell lymphomas was over 14 times higher.
FDA Adverse Event Reporting System (FAERS): An analysis of FAERS data found that CTCL was reported approximately 30 times more frequently for Dupixent than for all other medications combined. The FDA received over 300 CTCL reports linked to Dupixent and added the drug to its Potential Signals of Serious Risks list in March 2025.
Despite this evidence, Dupixent’s FDA-approved label contains no warning about CTCL or lymphoma risk. This is the central allegation in the current litigation: Sanofi and Regeneron had access to this data and failed to act.
This litigation is moving quickly. Here are the key developments:
No settlements or jury verdicts have been reached yet. However, once the MDL is formed and discovery begins, the litigation is expected to accelerate significantly.
No. Dupixent cases are being filed as individual lawsuits, not class actions. Each patient’s medical history, diagnosis, treatment timeline, and damages are unique, which makes individual claims the more appropriate path for pursuing full compensation.
That said, attorneys have filed a motion to consolidate these cases into a multidistrict litigation (MDL). An MDL is different from a class action — it centralizes pretrial proceedings like discovery and expert testimony before a single federal judge, but each plaintiff retains their individual claim and potential damages.
MDL consolidation is standard in pharmaceutical litigation and is expected to be the next major step in Dupixent cases.
You may have a claim if:
If you’re unsure whether your diagnosis is connected to Dupixent, that’s okay. Our attorneys review medical records, treatment timelines, and pathology results to evaluate whether a viable claim exists. The consultation is free and confidential.
Dupixent plaintiffs may be able to recover compensation for:
Because this litigation is still in its early stages with no settlements or verdicts on record, specific compensation amounts are difficult to project. In comparable pharmaceutical cancer cases, individual recoveries have ranged from six to seven figures depending on the severity of the diagnosis and damages.
Tennessee law gives you a limited window to take legal action. Under Tenn. Code § 28-3-104, the statute of limitations for product liability personal injury claims is one year from the date of injury — which in Dupixent cases means the date you were diagnosed with CTCL or a related cancer, not the date you started taking the drug.
This is a narrow deadline. If you’ve been diagnosed, speak with an attorney as soon as possible to protect your right to file a claim. Different deadlines may apply in other states.
The first Dupixent wrongful death lawsuit was filed here in Tennessee. As a Nashville-based personal injury law firm with attorneys licensed in Tennessee, Kentucky, Georgia, and Texas, The Higgins Firm is positioned to represent patients across multiple jurisdictions.
Dupixent generated over $13 billion in revenue in 2024 and is projected to surpass $20 billion in 2026. Despite mounting evidence of a serious cancer risk, its manufacturers have not added a single cancer warning to the drug’s label. Patients and their families deserve accountability.
If you or someone you love took Dupixent and developed CTCL or T-cell lymphoma, we want to hear from you. The consultation is free, and you pay nothing unless we win your case.
Contact The Higgins Firm for a free Dupixent case review.
The insurance company has a legal team. You should too.
You Have Questions. We Have Answers.
Dupixent lawsuits allege that Sanofi and Regeneron Pharmaceuticals failed to warn patients and doctors that the drug may increase the risk of cutaneous T-cell lymphoma (CTCL). Because CTCL symptoms closely resemble eczema, patients may have unknowingly had cancer while continuing treatment, allowing the disease to progress.
Multiple peer-reviewed studies have found that Dupixent users face a significantly higher risk of developing CTCL compared to non-users. The FDA has flagged this as a potential serious safety signal and is evaluating whether regulatory action is needed.
No. Dupixent has not been recalled. Patients currently taking Dupixent should not stop treatment without first consulting their doctor. The lawsuits focus on the manufacturers’ failure to warn about the CTCL risk, not on pulling the drug from the market.
There are no settlements or verdicts yet. Compensation will depend on individual factors including the severity of your diagnosis, treatment costs, lost income, and impact on quality of life. In similar pharmaceutical cancer litigation, recoveries have ranged from the low six figures to over $1 million in the most severe cases.
Tennessee’s statute of limitations for product liability claims is one year from the date of injury under Tenn. Code § 28-3-104. For Dupixent cases, that means one year from your CTCL diagnosis date. Other states have different deadlines — an attorney can help you determine your specific filing window.
